EMA/794400/2014

European Medicines Agency decision

P/0027/2015

of 30 January 2015

on the agreement of a paediatric investigation plan for recombinant human heparan N-sulfatase (rhHNS) (EMEA-001634-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0027/2015

of 30 January 2015

on the agreement of a paediatric investigation plan for recombinant human heparan N-sulfatase (rhHNS) (EMEA-001634-PIP01-14) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Shire Human Genetic Therapies AB on 9 April 2014 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 December 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human heparan N-sulfatase (rhHNS), solution for injection/infusion, intrathecal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Shire Human Genetic Therapies AB, Svärdvägen 11 D, SE-182 33 – Danderyd, Sweden.

Done at London, 30 January 2015

For the European Medicines Agency
Zaide Frias
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/595547/2014

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-001634-PIP01-14

Scope of the application

Active substance(s):

Recombinant human heparan N-sulfatase (rhHNS)

Condition(s):

Treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)

Pharmaceutical form(s):

Solution for injection/infusion

Route(s) of administration:

Intrathecal use

Name/corporate name of the PIP applicant:

Shire Human Genetic Therapies AB

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Shire Human Genetic Therapies AB submitted for agreement to the European Medicines Agency on 9 April 2014 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 21 May 2014.

Supplementary information was provided by the applicant on 19 September 2014. The applicant proposed modifications to the paediatric investigation plan.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 12 December 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)

2.1.1. Indication(s) targeted by the PIP

Long term intrathecal (IT) enzyme replacement therapy (ERT) in patients in early stage MPS IIIA disease or mild cognitive impairment as a result of the disease.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection/infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	**Study 1:** Juvenile toxicity study to evaluate repeat dose intrathecal administration of recombinant human heparan N-sulfatase from a toxicology and safety pharmacology perspective over six months (HGT-1410-09-001). **Study 2:** Pre- and post-natal development toxicity study to detect adverse events on the pregnant/lactating female on the development of the foetus and on the offspring consequent to exposure of the female from implantation through weaning.
Clinical studies	6	**Study 3**: Observational study to evaluate the course of disease progression in children from 1 to less than 18 years of age with mucopolysaccharidosis type IIIA (HGT-SAN-053).

		Study 4: Open-label, multiple dose trial to evaluate safety, tolerability and activity of recombinant human heparan N-sulfatase in children from 3 to less than 18 years of age with mucopolysaccharidosis type IIIA (HGT-SAN-055). **Study 5:** Open-label, multiple dose trial (extension of study 4) to evaluate safety, tolerability and activity of recombinant human heparan N-sulfatase in children from 3 to less than 18 years of age with mucopolysaccharidosis type IIIA (HGT-SAN-067). **Study 6:** Open-label, randomised, controlled trial with 2 active treatment arms to evaluate safety and efficacy, of recombinant human heparan N-sulfatase versus no treatment in children from 1 year to less than 4 years of age with mucopolysaccharidosis type IIIA (HGT-SAN-093). **Study 7:** Open-label, randomised trial with 2 active treatment arms (extension of study 6) to evaluate safety and efficacy of recombinant human heparan N-sulfatase in children from 1 year to less than 5 years of age with mucopolysaccharidosis type IIIA. **Study 8:** Open-label, historical controlled trial to evaluate pharmacokinetics, safety, efficacy and immunogenicity of recombinant human heparan N-sulfatase in children from birth to less than 18 years of age with mucopolysaccharidosis type IIIA.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2019
Deferral for one or more measures contained in the paediatric investigation plan:	No